2022
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.
Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. Clinical Cancer Research 2022, 28: 2587-2597. PMID: 35377948, PMCID: PMC9464605, DOI: 10.1158/1078-0432.ccr-21-3215.Peer-Reviewed Original ResearchConceptsBasal-like triple-negative breast cancerPathologic complete responseResidual diseaseNeoadjuvant durvalumabDNA damage repairSomatic mutationsBreast cancerWnt/β-cateninHigh expressionTriple-negative breast cancerBasal-Like TripleDoxorubicin/cyclophosphamideDNA repairTumor mutation burdenRNA sequencingEpithelial-mesenchymal transitionFive-gene signatureB-cell markersCancer driversEnrichment analysisNegative breast cancerDamage repairGene expressionJAK-STATCell cycle
2009
New biologics for psoriasis and psoriatic arthritis
Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatologic Therapy 2009, 22: 56-60. PMID: 19222517, DOI: 10.1111/j.1529-8019.2008.01216.x.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalArthritis, PsoriaticBiological ProductsClinical Trials as TopicDrug Delivery SystemsHumansPrevalencePsoriasisTumor Necrosis Factor-alphaConceptsPsoriatic arthritisPhase II studyNew biologic therapiesPrevalence of psoriasisSymptoms of psoriasisAlpha monoclonal antibodyTumor necrosis factorHuman tumor necrosis factorCertolizumab pegolBiologic therapyII studyJoint destructionInterleukin-23Rheumatoid arthritisInterleukin-12Radiographic evaluationTreatment optionsAlpha antibodyClinical trialsNecrosis factorNew biologicsArthritisPsoriasisMonoclonal antibodiesAntibodies